Abstract
Secukinumab is a significant advancement in the treatment of autoimmune disease, particularly psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. By targeting interleukin-17A(IL-17A), it offers a focused approach to mitigating inflammation. This article provides a comprehensive overview of Secukinumab, exploring its mechanism of action, clinical efficacy, safety profile, administration, and ongoing research aimed at expanding its therapeutic scope.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal For Multidisciplinary Research
Paper Title
Journal
Date
